It's been nearly a year since the European Society of Intensive Care Medicine and the Society of Critical Care Medicine introduced SEPSIS-3—a new consensus definition for sepsis—and the cleft between...
30 January 2017
27 January 2017
Cyclin D kinase 4/6 (CDK4/6) inhibitors have shown great improvement in extending progression-free survival (PFS) in patients with human epidermal growth factor-negative (HER2-) and hormonal receptor positive (HR+) metastatic breast...
24 January 2017
On January 20th, Bristol-Myers Squibb (BMS) and Merck & Co. settled a year-long patent fight over Keytruda (pembrolizumab). BMS claimed that Merck & Co. had infringed BMS and Ono’s patents...
23 January 2017
Antibiotic misuse has massively exacerbated the development of antibiotic resistance (ABR). Exposing bacteria to antibiotics risks the bacteria developing genes proving mechanisms of resistance such as the ability to produce...
16 January 2017
Roche’s Tecentriq was approved in May 2016 for the second-line treatment of locally advanced/metastatic urothelial cancer following prior failure on platinum-based doublet chemotherapy.
5 December 2016
On November 12, Merck & Co. announced results from its pivotal KEYNOTE-045 study investigating the use of Keytruda in second-line treatment of advanced bladder cancer patients who had failed prior...
5 October 2016
AbbVie will present new detailed results of the pivotal Phase III studies evaluating the efficacy and safety of elagolix in endometriosis-associated pain at the upcoming 72nd American Society for Reproductive...
12 September 2016
The US-based Professionalism and Integrity Program was developed with funding from the National Institutes of Health to help researchers who have made key ethical and professional failures to change their...
7 August 2016
According to new research by scientists at the University of California, Berkeley, copper plays an essential role in fat metabolism, breaking down fat cells so they can be used for...
2 August 2016
AstraZeneca has presented new positive clinical trial results for anifrolumab, an investigational monoclonal antibody that is under development for the treatment of moderate to severe lupus. Abi Millar speaks to...